Key Insights

Highlights

Treatment Research

7 treatments under study, led by Avutometinib

Research Leaders

5 sponsors active, led by Verastem, Inc.

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
Phase 2 (2)
Phase 3 (1)

Trial Status

Active Not Recruiting2
Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials
NCT06072781Phase 3Recruiting

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

NCT04625270Phase 2Active Not Recruiting

A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

SYF33f9dbbe981e4da0afcbe4f30a1cc11cPhase 2Active Not Recruiting

Open-Label Extension Study to Provide Continued Access to Avutometinib Alone or in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Showing all 3 trials

Research Network

Common Treatments

  • Avutometinib3
  • Defactinib3
  • Avutometinib Vs6766 And Defactinib1
  • Liposomal Doxorubicin1
  • Anastrozole1

Active Sponsors

  • Verastem, Inc.3
  • European Network of Gynaecological Oncological Trial Groups (ENGOT)2
  • GOG Foundation2
  • Australia New Zealand Gynaecological Oncology Group1
  • Korean Gynecologic Oncology Group1

Top Investigators

Related Conditions

  • Low Grade Ovarian Serous Adenocarcinoma1
  • Low Grade Serous Ovarian Cancer1
  • Ovarian Cancer1

Activity Timeline